CGCoralith García

Coralith García

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Coralith García has a total of 249 co-authors. Here are the top co-authors by number of shared publications:

  • Jan Jacobs

    Institute of Tropical Medicine, Antwerp, Belgium; Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium

    7 shared publications
  • Jan Jacobs

    Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

    7 shared publications
  • Fiorella Krapp

    Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia

    6 shared publications
  • Lizeth Astocondor

    Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia

    6 shared publications
  • Noemí Hinostroza

    Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia. Lima, Perú

    6 shared publications
  • Herbert L. DuPont

    University of Texas Medical School, and School of Public Health, Houston, TX 77083

    5 shared publications

Latest Publications

  • Open Access

    In vitro susceptibility testing of aztreonam-avibactam against predominantly NDM-producing Enterobacterales in Peru

    by Coralith Garcia, Yelinda Reyes, Lizeth Astocondor, Liliana Caytuiro, Maribel Riveros, Catherine Amaro, Stephanie Andrade, Luis Hernández, Roxana Sandoval, Giancarlo Peréz-Lazo, et al.

    Metallo-β-lactamase-producing Enterobacterales are distributed worldwide, but some Latin American countries show a higher prevalence. Aztreonam-avibactam (ATM-AVI) may be an option for treating these infections. To evaluate in vitro susceptibility to aztreonam (ATM) alone and ATM-AVI in carbapenem-non-susceptible Enterobacterales isolates, based on the type of carbapenemase production, we prospectively collected carbapenem-non-susceptible Enterobacterales isolates from Peruvian hospitals during 2023–2024. Identification and susceptibility testing were performed by commercial panels and disk diffusion. Carbapenemases were detected by immunochromatography. ATM and ATM-AVI MICs were determined using broth microdilution panels with avibactam fixed at 4 µg/mL. The non-susceptible isolates to ATM-AVI and those with double production of carbapenemases underwent whole-genome sequencing. A total of 438 Enterobacterales isolates were analyzed; carbapenemase production was detected in 422 (96.3%) and NDM was the most frequent (61.9%). Coproduction of NDM + KPC in K. pneumoniae and NDM + OXA-48-like in Escherichia coli was observed. Overall, 99.3% were susceptible to ATM-AVI; MIC 50 and MIC 90 were 0.12 and 2 µg/mL, respectively. Overall, K. pneumoniae isolates had lower MIC 50 and MIC 90 values to ATM-AVI (0.12 and 0.5 µg/mL) compared to E. coli (0.5 and 4 µg/mL). Three E. coli isolates were resistant to ATM-AVI (MIC ≥ 8 µg/mL), they belonged to ST410, ST167, and ST10 and harbored a YRIN insertion in PBP3 along with CYM-type, PER-type, and CTX-M-type beta-lactamase genes. ATM-AVI demonstrated potent activity against carbapenem-non-susceptible Enterobacterales , including those producing NDM, which is the carbapenemase most frequently detected in Peruvian hospitals. IMPORTANCE: Enterobacterales isolates cause common illnesses in humans. Carbapenems are the antibiotics used to treat several of these infections, and increasingly, isolates resistant to these antibiotics are found. The most important mechanism of resistance to carbapenem among Enterobacterales is the production of enzymes called carbapenemases. Our results allowed us to recognize that NDM is the most frequent type of carbapenemase detected. Most of the antimicrobials available do not cover the E nterobacterales carrying NDM carbapenemase. In this scenario, we found that the new combination of drugs, aztreonam-avibactam, has high in vitro efficacy against most of the carbapenem-resistant isolates and against those isolates carrying NDM carbapenemase.

  • Open Access

    Rol de los actores clave para el proceso óptimo de hemocultivo: desde el médico hasta el laboratorio de microbiología

    by Coralith Garcia, Lizeth Astocondor, Noemi Hinostroza, Valeria Gordillo-Leo, Fiorella Krapp

    El hemocultivo es una herramienta fundamental para el diagnóstico de las infecciones del torrente sanguíneo. En este artículo se evalúan los aspectos del proceso de hemocultivos haciendo énfasis en el rol crítico que cumplen los trabajadores de la salud involucrados, incluyendo: el médico, quien debe conocer cuáles son las indicaciones; el flebotomista —que en los hospitales puede ser desempeñado por diferentes grupos incluyendo técnicos, médicos o enfermeras—, quien deben realizar el proceso utilizando una técnica aséptica; y el personal del laboratorio de microbiología, que debe seguir los procesos adecuados para obtener el resultado microbiológico. Adicionalmente, se revisa el rol del laboratorio de microbiología para evaluar y monitorear los indicadores de calidad de los hemocultivos, como son el volumen de sangre por botella, el porcentaje de positividad y el porcentaje de contaminantes, con el objetivo de optimizar el uso de esta herramienta diagnóstica.

  • Open Access

    Retos en investigación para los estudiantes de pregrado: “estamos en comunidad , no en solitario”.

    by Guillermo Salvatierra, Coralith Garcia Apac, José Oswaldo Cabanillas Angulo, Maria Edith Solis-Castro, Luz M. Moyano Vidal

    La investigación es el pilar fundamental en la formación de los estudiantes de las Escuelas de Medicina Humana y su integración en la curricula tiene como objetivo fortalecer el pensamiento crítico, la toma de decisiones basada en evidencia y el desarrollo de conocimiento orientado a resolver problemas sanitarios locales. Sin embargo, los estudiantes enfrentan numerosas barreras que dificultan la sostenibilidad y efectividad de esta integración. Estudios en Pakistán y Jordania en estudiantes de medicina identificaron barreras comunes en investigación, tales como: la falta de conocimiento metodológico (90 %), la ausencia de mentores capacitados (~86 %), la sobrecarga académica (> 88 %), una mentoría limitada (85,7 % ) y los limitados recursos financieros y acceso a bases de datos. (1–3) Los problemas institucionales de Perú, como la escasa financiación, los limitados recursos de investigación, la inadecuada gestión y supervisión estatal y las inadecuadas políticas institucionales, se traducen en una escasa producción científica y una limitada visibilidad internacional. (4,5). Las barreras identificadas en nuestro país son similares a las descritas en medio oriente y estas limitaciones impactan negativamente en la productividad científica.(6,7) Aprovechando el desarrollo de la XIII Jornada científica y de investigación de la Universidad Nacional de Tumbes, realizada los días 19-20 de junio; se llevó a cabo una mesa redonda organizada por la Sociedad Científica de Estudiantes de Medicina Humana, bajo el liderazgo de la estudiante Annia Valeria Silva Calderón. Durante esta actividad, se formularon seis preguntas clave a cinco docentes investigadores procedentes de diversas universidades públicas y privadas del país. La discusión giró en torno a los Retos que enfrentan los estudiantes de pregrado para insertarse en la investigación, temática que da título a esta editorial. (ver figuras 1 y 2)

  • Open Access

    Candidemia and antifungal susceptibility in Peruvian hospitals

    by Romina Rios-Blanco, Marcello Olsen-Verme, Fiorella Palomino Escalante, Michelle Regal Ludowieg, Jan Jacobs, Fiorella Krapp Lopez, Beatriz Bustamante Rufino, Coralith García Apac

    Worldwide, Candida bloodstream infections have presented an increase in non-albicans Candida species and resistance to antifungal agents. Objective: To describe the microbiological characteristics of consecutive Candida blood culture isolates. Methods: This study analyzed 73 consecutive Candida blood isolates recovered between July 2017 and July 2019 from routine patient care at 15 Peruvian hospitals, assessing susceptibility to four antifungal agents. Results: The species most frequently detected were Candida parapsilosis 39 (53.4%), Candida albicans 23 (31.5%), and Candida tropicalis 5 (6.8%). Conclusions: All isolates were susceptible to amphotericin B, fluconazole, voriconazole, and anidulafungin. There is a predominance of non-albicans Candida cases in Peru and a high susceptibility to current antifungal drugs.

  • Methicillin-Resistant Staphylococcus aureus Bloodstream Infections in Hospitalized Patients in Peru

    by Coralith García, Noemí Hinostroza, Valeria Gordillo, Maria L. Inchaustegui, Lizeth Astocondor, Omayra Chincha, Saúl Alejos, Marco Olivera, Digna Bojórquez-Fernández, Fátima Concha-Velasco, et al.

    : There is a knowledge gap in the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) causing bloodstream infections (BSIs) in Peru. Through a surveillance study in 13 hospitals of 10 Peruvian regions (2017–2019), we assessed the proportion of MRSA among S. aureus BSIs as well as the molecular typing of the isolates. A total of 166 S. aureus isolates were collected, and 36.1% of them were MRSA. Of note, MRSA isolates with phenotypic and genetic characteristics of the hospital-associated Chilean-Cordobes clone (multidrug-resistant SCCmec I, non–Panton-Valentine leukocidin [PVL] producers) were most commonly found (70%), five isolates with genetic characteristics of community-associated MRSA (CA-MRSA)—SCCmec IV, PVL-producer—(8.3%) were seen in three separate regions. These results demonstrate that hospital-associated MRSA is the most frequent MRSA found in patients with BSIs in Peru. They also show the emergence of S. aureus with genetic characteristics of CA-MRSA. Further studies are needed to evaluate the extension of CA-MRSA dissemination in Peru.


  • Open Access

    Prevalence of Antimicrobial Resistance in Gram-Negative Bacteria Bloodstream Infections in Peru and Associated Outcomes: VIRAPERU Study

    by Fiorella Krapp, Coralith García, Noemi Hinostroza, Lizeth Astocondor, Claudia R. Rondon, Brecht Ingelbeen, Hugo A. Alpaca-Salvador, Catherine Amaro, Carla Aguado Ventura, Evelyn Barco-Yaipén, et al.

    : Surveillance of antimicrobial resistance among gram-negative bacteria (GNB) is of critical importance, but data for Peru are not available. To fill this gap, a non-interventional hospital-based surveillance study was conducted in 15 hospitals across Peru from July 2017 to October 2019. Consecutive unique blood culture isolates of key GNB (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter spp.) recovered from hospitalized patients were collected for centralized antimicrobial susceptibility testing, along with linked epidemiological and clinical data. A total of 449 isolates were included in the analysis. Resistance to third-generation cephalosporins (3GCs) was present in 266 (59.2%) GNB isolates. Among E. coli (n = 199), 68.3% showed 3GC resistance (i.e., above the median ratio for low- and middle-income countries in 2020 for this sustainable development goal indicator). Carbapenem resistance was present in 74 (16.5%) GNB isolates, with wide variation among species (0% in E. coli, 11.0% in K. pneumoniae, 37.0% in P. aeruginosa, and 60.8% in Acinetobacter spp. isolates). Co-resistance to carbapenems and colistin was found in seven (1.6%) GNB isolates. Empiric treatment covered the causative GNB in 63.3% of 215 cases. The in-hospital case fatality ratio was 33.3% (92/276). Pseudomonas aeruginosa species and carbapenem resistance were associated with higher risk of in-hospital death. In conclusion, an important proportion of bloodstream infections in Peru are caused by highly resistant GNB and are associated with high in-hospital mortality.


  • Open Access

    Frecuencia de Staphylococcus aureus meticilinorresistente adquirido en la comunidad en un hospital de tercer nivel en Perú

    by Lucía Cabrejos-Hirashima, Camila Vives-Kufoy, Jaycia Inga-Salazar, Lizeth Astocondor, Noemi Hinostroza, Coralith García

    Con el objetivo de determinar la frecuencia de aislamientos de Staphylococcus aureus meticilinorresistente adquirido en la comunidad (MRSA-AC) y describir el patrón de resistencia antimicrobiana y de genotipo, se realizó un estudio transversal en el 2017 en el Hospital Nacional Cayetano Heredia en Lima, Perú. De los 115 aislamientos de S. aureus analizados, se determinó una frecuencia de MRSA del 46,1%, la mayoría provenientes de secreciones de diferentes tipos (26,4%) y sangre (18,9%). Se encontró alta corresistencia (75%) a clindamicina, eritromicina, gentamicina y ciprofloxacina entre los aislamientos de MRSA. Según la tipificación de SCCmec, la mayoría correspondían a cepas de MRSA adquirido en un hospital (MRSA-AH) y, solo un pequeño grupo (2,6%) correspondían a MRSA-AC. A pesar de la baja frecuencia descrita con relación a países vecinos (27%), es necesario mantener una adecuada vigilancia epidemiológica local para evitar la propagación local de MRSA-AC.


  • Open Access

    Estandarización y validación de una prueba molecular RT-LAMP in house para el diagnóstico de SARS-CoV-2

    by Oscar Escalante-Maldonado, Margot Vidal-Anzardo, Fernando Donaires, Gilmer Solis-Sanchez, Italo Gallesi, Luis Pampa-Espinoza, Maribel Huaringa, Nancy Rojas-Serrano, Coralih García, Eddie Angles-Yanqui, et al.

    Objetivos: Estandarizar una prueba RT-LAMP in house para la detección de SARS-CoV-2 y validarla con muestras de laboratorio y de campo en pacientes con sospecha clínica de COVID-19. Materiales y métodos: Se estandarizó una prueba molecular RT-LAMP in house para la detección de SARS-CoV-2 estableciéndose el límite de detección con células Vero de cepas peruanas aisladas de SARS-CoV-2. Se validó la prueba en laboratorio con 384 muestras de hisopado nasal y faríngeo (HNF) obtenidas entre marzo y julio de 2020. Para la validación de campo se obtuvieron muestras de HNF de 383 casos sintomáticos sospechosos de COVID-19. Todas las muestras fueron evaluadas por RT-LAMP y RT-qPCR. Para la validación de laboratorio y de campo se consideró como estándar de referencia al RT-qPCR, se calcularon medidas de concordancia y rendimiento diagnóstico. Resultados: El límite de detección fue consistente en los casos con umbral de ciclo (Ct) Ct 30 en ambas pruebas, mostrando eficiencia para detectar hasta 1000 copias/μL del gen diana. Se evidenció robustez con la mitad de las concentraciones de cebadores y 20 μL de volumen final. Se identificó ausencia de amplificación para otros coronavirus humanos. La concordancia en laboratorio obtuvo un Kappa de 0,88 (IC 95%: 0,83–0,93) y en campo fue de 0,89 (IC 95%: 0,84−0,94); la sensibilidad en laboratorio fue de 87,4% (IC 95%: 80,8−92,4) y en campo fue de 88,1% (IC 95%: 81,6−92,9), la especificidad en ambos escenarios fue de 98,8% (IC 95%: 96,4−99,7). Conclusiones: La prueba RT-LAMP in house fue validada por presentar una adecuada robustez, sin reacciones cruzadas, buena concordancia y rendimiento diagnóstico comparado con el RT-qPCR.


  • Open Access

    Reverse Transcription-Loop-Mediated Isothermal Amplification (RT-LAMP) is an effective alternative for SARS-CoV-2 molecular detection in middle-income countries

    by Oscar Escalante-Maldonado, Margot Vidal-Anzardo, Fernando Donaires, Gilmer Solis-Sanchez, Italo Gallesi, Luis Pampa-Espinoza, Maribel Huaringa, Nancy Rojas Serrano, Coralith García, Eddie Angles-Yanqui, et al.

    Molecular diagnosis of SARS-CoV-2 in developing countries is still a big challenge. The reference standard, RT-qPCR, recommended by WHO, is not widely available, difficulting early identification of cases. Furthermore, the transport logistic between the sample collection point and the laboratory facilities can alter the samples, producing false negative results. RT-LAMP is a cheaper, simpler molecular technique that can be an interesting alternative to be offered in hospital laboratories. We present the evaluation of a RT-LAMP for diagnosis of SARS-CoV-2 in two steps: the laboratory standardization and the clinical validation, comparing it with the standard RT-qPCR. In the standardization phase, limit of detection and robustness values were obtained using RNA from a Peruvian SARS-CoV-2 strain. It presented 100% agreement between triplicates (RT-LAMP agreement with all RT-qPCR reactions that presented Ct ≤ 30) and robustness (RT-LAMP successful reactions with 80% reaction volume and 50% primer concentration). 384 nasal and pharyngeal swabs collected from symptomatic patients and stored in the INS biobank were tested and we obtained 98.75%, 87.41%, 97.65% and 92.96% for specificity, sensitivity, positive predictive value and negative predictive values respectively. Then, 383 samples from symptomatic patients with less than 15 days of disease, were tested both with the RT-LAMP and with the RT-qPCR, obtaining e 98.8%, 88.1%, 97.7% y 93.3% of specificity, sensitivity, positive predictive value and negative predictive values respectively. The laboratory standardization and the clinical validation presented the same value by Kappa-Cohen index (0.88) indicating an almost perfect agreement between RT-LAMP and RT-qPCR for molecular detection of SARS-CoV-2. We conclude that this RT-LAMP protocol presented high diagnostic performance values and can be an effective alternative for COVID-19 molecular diagnosis in hospitals, contributing to early diagnosis and reducing the spread of virus transmission in the Peruvian population.